Search

Displaying results 4201 - 4210 of 4822 in total
  1. Drug

    Z-Val-Ala-Asp fluoromethyl ketone

    go.drugbank.com/drugs/DB07744
    Experimental

    It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.

  2. Drug

    Pyruvaldehyde

    go.drugbank.com/drugs/DB03587
    Experimental

    It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]

  3. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613].

  4. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984).

  5. Drug

    Luveltamab tazevibulin

    go.drugbank.com/drugs/DB17563
    Investigational

    [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

  6. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

  7. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has sh...

  8. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.

  9. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]

  10. Drug

    mRNA-3927

    go.drugbank.com/drugs/DB17669
    Investigational

    Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.[L45998]